Jul 29, 2019 17:49 JST

Source: NEC Corporation

NEC Acquires Norwegian Bioinformatics Company, OncoImmunity AS

TOKYO, Jul 29, 2019 - (JCN Newswire) - NEC Corporation (TSE: 6701) has announced the acquisition of OncoImmunity AS, a Norway-based bioinformatics company that develops proprietary machine learning software to support the fight against cancer. OncoImmunity AS will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS.

OncoImmunity AS, founded in 2014, is a bioinformatics company dedicated to the development of software solutions that facilitate the effective selection of patients for cancer immunotherapy, and identify optimal neoantigen targets for truly personalized cancer vaccines and cell therapies in a clinically actionable time frame.

NEC announced its business strategy surrounding its AI-driven drug discovery business in May 2019. This acquisition is integral for enhancing the resources and capabilities that support the development of its individualized immunotherapy pipelines. NEC will maintain its focus on drug discovery, while NEC OncoImmunity AS continues its neoantigen prediction services.

Sharing a common vision, both NEC and OncoImmunity AS firmly believe in improving individualized cancer treatments through Artificial Intelligence (AI). AI holds great promise in enabling each and every patient to receive the most appropriate medication.

"The OncoImmunity AS team are delighted to be joining the NEC Group and firmly believe that the union will realize great synergies, marrying the mutual strengths of OncoImmunity AS's and NEC's neoantigen prediction pipelines with NEC's expertise in AI, data management and security. These synergies will help strengthen NEC's individualized immunotherapy programs, whilst simultaneously positioning NEC OncoImmunity AS as the leading neoantigen prediction service provider in the field," said Dr. Richard Stratford, Chief Executive Officer and Co-founder of OncoImmunity AS.

"NEC strongly believes that healthcare based on genomics paves the way for individualized medicine. OncoImmunity AS is a recognized player in the neoantigen prediction field, and their compelling systems are expected to form valuable synergies with NEC. We are confident that this acceleration of development will provide promising new avenues that lead to better cancer treatments," said Osamu Fujikawa, Senior Vice President, NEC Corporation.

Contact:
NEC 
Seiichiro Toda         
s-toda@cj.jp.nec.com 
+81-3-3798-6511
Source: NEC Corporation
Sectors: CyberSecurity

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


NEC Launches Orbital Transfer Vehicle Development Project Aiming for Asia's First Vehicle Deployment through JAXA's Space Strategy Fund Program
May 15 2026 13:55 JST
 
NEC Launches "Africa Corporate Innovation Program" Accelerating Business Through Co-Creation with African Startups
April 28 2026 18:05 JST
 
NEC Announces Strategic Collaboration with Anthropic Focused on Enterprise AI
April 23 2026 16:46 JST
 
NEC Receives Company of the Year recognition in Global Biometric Solutions from Frost & Sullivan
April 22 2026 13:46 JST
 
NEC to Supply Nine Types of Defense Equipment for Tthree Australian Frigates
April 19 2026 11:10 JST
 
IFS and NEC to Deploy Next-Generation Core System IFS Cloud for Hoshizaki
April 10 2026 09:10 JST
 
NEC's Automated Negotiation AI recognized as a Use Case in Gartner(R) Research
April 09 2026 12:41 JST
 
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
April 03 2026 11:33 JST
 
NEC Supports Ooredoo Algeria in Modernizing Enterprise Network Security with high-performance next-generation firewalls (NGFW)
March 31 2026 09:50 JST
 
Royal Healthcare in Singapore provides NEC's "FonesVisuas Test" for Disease Risk Prediction
March 26 2026 10:21 JST
 
More Press release >>

Latest Press Release


More Latest Release >>